Rocket Pharmaceuticals In... (RCKT)
7.16
0.19 (2.73%)
At close: Apr 23, 2025, 3:59 PM
7.26
1.38%
After-hours: Apr 23, 2025, 07:27 PM EDT
2.73% (1D)
| Bid | 7.15 |
| Market Cap | 763.47M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -258.75M |
| EPS (ttm) | -2.73 |
| PE Ratio (ttm) | -2.62 |
| Forward PE | -4.33 |
| Analyst | Buy |
| Ask | 7.4 |
| Volume | 2,996,416 |
| Avg. Volume (20D) | 2,314,306 |
| Open | 7.24 |
| Previous Close | 6.97 |
| Day's Range | 7.00 - 7.44 |
| 52-Week Range | 4.55 - 26.98 |
| Beta | 1.00 |
About RCKT
Rocket Pharmaceuticals, Inc., together with its subsidiaries, operates as a multi-platform biotechnology company that focuses on developing gene therapies for rare and devastating diseases. It has three clinical-stage ex vivo lentiviral vector programs for fanconi anemia, a genetic defect in the bone marrow that reduces production of blood cells or promotes the production of faulty blood cells; leukocyte adhesion deficiency-I, a genetic disorder ...
Industry Biotechnology
Sector Healthcare
IPO Date Feb 18, 2015
Employees 299
Stock Exchange NASDAQ
Ticker Symbol RCKT
Website https://rocketpharma.com
Analyst Forecast
According to 10 analyst ratings, the average rating for RCKT stock is "Buy." The 12-month stock price forecast is $47, which is an increase of 556.42% from the latest price.
Stock ForecastsNext Earnings Release
Rocket Pharmaceuticals Inc. is scheduled to release its earnings on May 5, 2025,
during market hours.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
4 months ago
-2.38%
Rocket Pharmaceuticals shares are trading lower af...
Unlock content with
Pro Subscription
6 months ago
+8.27%
Rocket Pharmaceuticals shares are trading higher after Scotiabank initiated coverage on the stock with a Sector Outperform rating on the stock and announced a $50 price target.
